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ArizonaABSTRACT The myocardium undergoes extensive metabolic and energetic remodeling during the progression of cardiac dis-
ease. Central to remodeling are changes in the adenine nucleotide pool. Fluctuations in these pools can activate AMP-activated
protein kinase (AMPK), the central regulator of cellular energetics. Binding of AMP to AMPK not only allosterically activates
AMPK but also promotes phosphorylation of AMPK by an upstream kinase complex, LKB1/Mo25/STRAD (liver kinase B 1,
mouse protein 25, STE-related adaptor protein). AMPK phosphorylation by the LKB1 complex results in a substantial increase
in AMPK activity. Molecular targeting by the LKB1 complex depends on subcellular localization and transcriptional expression.
Yet, little is known about the ability of the LKB1 complex to modulate targeting of AMPK after activation. Accordingly, we hypoth-
esized that differing stoichiometric ratios of LKB1 activator complex to AMPK would uniquely impact myofilament function.
Demembranated rat cardiac trabeculae were incubated with varying ratios of the LKB1 complex to AMPK or the LKB1 complex
alone. After incubation, we measured the Ca2þ sensitivity of tension, rate constant for tension redevelopment, maximum tension
generation, length-dependent activation, cooperativity, and sarcomeric protein phosphorylation status. We found that the Ca2þ
sensitivity of tension and cross-bridge dynamics were dependent on the LKB1 complex/AMPK ratio. We also found that the
LKB1 complex desensitizes and suppresses myofilament function independently of AMPK. A phospho-proteomic analysis of
myofilament proteins revealed site-specific changes in cardiac Troponin I (cTnI) phosphorylation, as well as a unique distribution
of cTnI phosphospecies that were dependent on the LKB1 complex/ AMPK ratio. Fibers treated with the LKB1 complex alone did
not alter cTnI phosphorylation or phosphospecies distribution. However, LKB1 complex treatment independent of AMPK
increased phosphorylation of myosin-binding protein C. Therefore, we conclude that the LKB1/AMPK signaling axis is able to
alter muscle function through multiple mechanisms.INTRODUCTIONDuring the progression of cardiac disease, the myocardium
undergoes cellular and molecular remodeling, including a
changing metabolic and energetic landscape (1,2). Central
to energetic remodeling is an alteration in the production
and use of ATP. The molecular underpinnings of the
metabolic derangements that occur during cardiac disease
involve changes in the mediators of ATP generation, utili-
zation, and delivery. In general, creatine kinase (CK)
reversibly and rapidly converts ADP and phosphocreatine
(PCr) to ATP and creatine (Cr) (3). In a parallel reaction,
adenylate kinase (AK) mediates a complementary intracel-
lular phosphotransfer, promoting a high-energy Pi transfer
from ADP to ATP (leaving an increasing [AMP] pool)
via distinct isoforms with different cellular localizations
(4,5).
As cardiac disease ensues, the loss of total Cr and PCr
results in elevated [ADP] and [AMP] even if [ATP] is
maintained (6). Further along the disease process, CK ac-
tivity is reduced, leading to a gradual decrease in cellularSubmitted October 7, 2014, and accepted for publication February 2, 2015.
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0006-3495/15/03/1484/11 $2.00[ATP] (7). Interestingly, the amount and activity of AK
do not change in heart disease, which may be a compensa-
tory mechanism in response to declining CK levels (4).
Considering the relatively high rate of ATP synthesis in
the heart (2), a gradual decrease in [ATP] can cause dispro-
portionate energetic deficiencies (8,9). Such changes in en-
ergetics limit contractile reserve and the ability to power
myocellular ATPases, which are necessary to support con-
tractile function.
AMP-activated protein kinase (AMPK) has emerged as
a key nongenomic, posttranslational regulator of cellular
energy homeostasis. AMPK is a phylogenetically conserved
heterotrimeric complex that consists of a catalytic a subunit
and regulatory b and g subunits (10). An increase in myo-
cellular [AMP], as occurs with cardiac disease, allosteri-
cally activates AMPK and permits phosphorylation of the
a catalytic subunit at thr172 by the upstream liver kinase
B1 (LKB1) kinase complex (11–13). LKB1 acts in concert
with Mo25 (mouse protein 25) and STRAD (ste-related
adaptor protein) to phosphorylate AMPK, potentiating
its activity and promoting ATP-producing pathways while
inhibiting ATP-consuming pathways (12,13). In addition,
AMPK targets ser150 of cardiac Troponin I (cTnI) andhttp://dx.doi.org/10.1016/j.bpj.2015.02.012
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(14–16). Therefore, AMPK could not only respond to
changes in CK and AK activity through changes in the
ATP pool but could also directly tune myofilament function
to the energetic demand through posttranslational modifica-
tions (PTMs).
Because of its energy-freeing reactions, AMPK is an
attractive therapeutic target for heart failure. Indeed,
AMPK activation promotes survival in ischemia-induced
heart failure (17). We propose that a potential mechanism
by which AMPK protects the heart during cardiac disease
is by acting as a nodal point for sensing changes in cellular
energetics and then appropriately targeting the contractile
apparatus to alter contractility. However, exploring the
mechanism of AMPK-based protection against heart failure
is complicated by two critical findings: 1) CK and AK
enzymes are localized to the myofilaments (4,18), and 2)
stoichiometry of the upstream activator LKB1/Mo25/
STRAD complex (LKB1 complex) and AMPK drives
AMPK-target activity (19,20). This suggests that both
localized adenine nucleotides pools and the stoichiometric
activator complex are indispensable for driving AMPK-
dependent targeting of myofilament proteins. Although
we are pursuing the former concept, in this work we pro-
vide a novel (to our knowledge) insight into the latter
one. In this study, we hypothesized that differing stoichio-
metric ratios of the LKB1 activator complex to AMPK
would uniquely impact myofilament function. To examine
this hypothesis, we assessed the Ca2þ sensitivity of tension,
rate constant for tension redevelopment, maximum tension
generation, length-dependent activation (LDA), and coop-
erativity in demembranated cardiac trabeculae after treat-
ment with varying ratios of LKB1 complex to activated
AMPK. In addition, we measured the phosphorylation
pattern of myofilament proteins. We show that the Ca2þ
sensitivity of tension and cross-bridge dynamics is depen-
dent on the LKB1 complex/AMPK ratio. Unexpectedly,
we show that the LKB1 complex can uniquely desensitize
and suppress myofilament function independently of acti-
vating AMPK. The results of a phospho-proteomic analysis
provide insight into the underlying mechanism of these
observations.MATERIALS AND METHODS
Muscle mechanics
Cardiac muscle preparation
Two-month-old male Sprague-Dawley rats were anesthetized with isoflur-
ane and their hearts were rapidly excised. The hearts were then retrogradely
perfused with a modified Krebs-Henseleit solution (NaCl 118.5 mM, KCl
5 mM, MgSO4 1.2 mM, NaH2PO4 2 mM, D-(þ)-glucose 10 mM, NaHCO3
25 mM, CaCl2 0.2 mM, and 2,3-butanedione monoxime 20 mM) (21). Thin,
even, free-standing trabeculae were isolated from the right ventricular
wall and left ventricular papillaries. After isolation, the trabeculae and
cut papillaries were transferred to an ice-cold relaxing solution (Table S1in the Supporting Material) containing 1% Triton X-100 for overnight
demembranation at 4C.
Activation and treatment of AMPK
Separate protocols were used to activate the AMPK complex. In one pro-
tocol, 20 nM of LKB1/Mo25/STRAD (LKB1 complex; Millipore, Darm-
stadt, Germany) was added to 100 nM of AMPK (a1b1g1; Calbiochem,
Darmstadt, Germany) in kinase reaction buffer (60 mM HEPES pH 7.5,
3 mM MgCl2, 3 mM Na3VO4, 1.2 mM DTT, 500 mM ATP, 10 mM
EGTA, 5 mm NaF, 100 mM ADP, protease inhibitor cocktail (Sigma, St.
Louis, MO), and 1 mM protein kinase A (PKA) inhibitor (Sigma) to pre-
vent endogenous PKA activity) for 10 min at 37C. In the second protocol,
100 nM of LKB1 complex was added to 100 nM of AMPK in the afore-
mentioned kinase reaction buffer for 10 min at 37C. Both protocols re-
sulted in saturating levels of AMPK activation as measured by a direct
AMPK kinase assay (data not shown) (20). As a control, 100 nM of the
LKB1 complex in the absence of exogenous AMPK was used. To test
how different stoichiometric ratios of the LKB1 to AMPK complex impact
myofilament function, we incubated skinned trabeculae or papillaries with
activated AMPK and either low LKB1 (10 nM LKB1:50 nM AMPK), high
LKB1 (50 nM LKB1:50 nM AMPK), or the LKB1 complex alone (50 nM
LKB1) in the kinase reaction buffer for 30 min at 30C. After incubation,
fibers were washed (15 min; repeated three times) with standard relaxing
buffer on ice.
Experimental apparatus and protocol
The experimental apparatus used for mechanical measurements of cardiac
trabeculae was similar to one described previously by Konhilas et al. (21)
(Supporting Material). The Ca2þ sensitivity of tension development was
determined by activating the muscle during a series of preactivating-acti-
vating-relaxation cycles using a range of free [Ca2þ] in the activating so-
lutions (Table S1) selected in random order (21). Sarcomere length (SL)
was set at either 2.2 mm or 2.0 mm, as determined from the first-order He-
Ne laser light diffraction band monitored by a 2048 pixel high-speed
linear CCD sensor (Dexela Ltd., London, UK). Fibers reached steady-
state tension and then were rapidly slackened by 20% of total fiber length.
The difference between steady-state tension and slacked tension is the to-
tal tension (Fig. S1 A). Active tension is the difference between the total
tension and relaxed, passive tension. To determine the rate constant for
tension redevelopment (ktr), fibers reached steady-state tension at
maximal and submaximal [Ca2þ] under controlled SL (2.2 mm) and
then subjected to a rapid release-restretch protocol (Fig. S1 B). Fibers
that did not retain 85% of initial maximal tension or a diffraction pattern
were discarded. Given these stringent criteria, the yields for mechanical
experiments were ~10%. Upon completion of each protocol, tissue was
flash-frozen in liquid nitrogen and stored at 80C for proteomic
analysis.Proteomic analysis
Sample preparation for SDS-PAGE and phospho-affinity
SDS-PAGE
Myofibrillar proteins from frozen trabeculae or papillaries were isolated as
detailed previously (22). An RC-DC assay (Bio-Rad, Hercules, CA) was
performed to determine protein concentrations.
ProQ Diamond phosphoprotein stain
SDS-PAGE was used to separate myofibrillar proteins and measure
phosphorylation status as detailed previously (23). After SDS-PAGE,
gels were fixed and stained according to manufacturer’s (Invitrogen,
Grand Island, NY) instructions. After phosphoprotein staining, gels
were stained for total protein with Coomassie Brilliant Blue. Phospho-
rylated protein optical densities were quantified using LabImage 1DBiophysical Journal 108(6) 1484–1494
1486 Behunin et al.software and normalized to their respective Coomassie-stained total
protein bands.
Western blot analysis
SDS-PAGE was used to separate myofibrillar samples. After transfer, total
protein was measured with Ponceau S stain (Sigma). Antibodies were used
to probe for total cTnI (AbCam Cambridge, UK; 1:5000), phospho-ser23/24
cTnI (Cell Signaling, Beverly, MA; 1:1000), phospho-ser150 cTnI (AbCam,
1:500), phospho-ser43cTnI (AbCam, 1:125), phospho-ser282 myosin-bind-
ing protein C (MBPC, 1:1000; Enzo Life Sciences, Farmingdale, NY),
and total MBPC (Abcam, 1:1000). Protein optical densities were quantified
using LabImage 1D software and normalized to total protein to adjust
for alterations in loading parameters. Normalized optical densities from
phospho-ser23/24cTnI, phospho-ser150cTnI, and phospho-ser43 cTnI were
divided by the total cTnI optical density. In a similar manner, optical
densities from phospho-ser282 MBPC were divided by the total protein C
optical density.
All immunoblot analysis was performed from the semiquantitation of
individual blots and was not compared across blots according to accepted
guidelines. Some immunoblot images of a given target were cropped
from the same blot to conserve figure space and avoid redundancy. All
samples used for statistical analysis were obtained from different animals
(no comparisons included two samples from the same rat).
Phosphate-affinity SDS-PAGE
Phosphate-affinity SDS-PAGE (Wako Pure Chemical Industries, Richmond,
VA) was performed according to the manufacturer’s instructions and as
described previously (24–26). Membranes were probed for total cTnI
(1:5000), phospho-ser23/24cTnI (1:1000), and phospho-ser150cTnI (AbCam;
1:500). Total protein was measured by either SYPRO Ruby Protein Blot
stain (Bio-Rad) or Ponceau S solution (Sigma). Human recombinant cTnI
(hcTnI, kindly provided by Dr. Jil Tardiff) and rat cardiomyocytes treated
with PKA (catalytic subunit, 1 U/mL)were used as relative standards to iden-
tify different phosphospecies populations (SupportingMaterial). The optical
densities of the phosphospecieswere quantifiedusingLabImage 1Dsoftware
and normalized to their SYPRO or Ponceau total protein bands. Each phos-
phospecies was normalized to their respective total cTnI optical density.FIGURE 1 Ca2þ sensitivity of tension development in untreated and
treated demembranated cardiac trabeculae. (A) Ca2þ sensitivity of tensionData and statistical analysis
Tension in submaximally activating solutions was expressed as fractions
(Frel) of the maximum tension (F0) at the same SL. The F0 value used to
normalize submaximal tension was obtained by linear interpolation be-
tween successive maximal activations. Each individual Ca2þ-tension rela-
tionship was fit to a modified Hill equation where Frel ¼ [Ca2þ]n/
(EC50
n þ [Ca2þ]n), Frel ¼ relative tension, EC50 ¼ [Ca2þ] at which tension
is half-maximal, n ¼ slope of the Ca2þ-tension relationship (Hill co-
efficient). The DEC50 was calculated as the difference in EC50 at SL ¼
2.0 mm and 2.2 mm for each experiment. Likewise, the DpCa50 was calcu-
lated as the difference in pCa50 (–log [EC50]) at SL ¼ 2.0 mm and 2.2 mm.
Tension redevelopment after the release and restretch protocol (ktr) was fit
to a monoexponential function given by F ¼ (F0  Fres)(1  ektrt) þ Fres,
where F0 is the steady-state isometric tension and Fres is the residual tension
from which the fiber starts to redevelop tension. Results are presented as
mean 5 SEM. One-way ANOVA with Tukey’s post hoc test was used to
determine differences in means. Multiple linear regression was also used
to determine the relationship between ktr and tension, and p-values less
than 0.05 were considered significant.
in trabeculae treated with low levels of LKB1 complex activation of
AMPK (open diamonds, rAMPK/LKB1lo) and high levels of LKB1 com-
plex activation (open squares, rAMPK/LKB1hi) compared with untreated
fibers (solid circles, untreated). (B) Ca2þ sensitivity of tension in trabeculae
treated with only the LKB1 complex (open circles) compared with
untreated fibers (solid circles). SL was set to 2.2 mm and all data were
normalized to saturating Ca2þ (maximal) tension.Animal subjects
All experiments were performed using protocols approved by the Institu-
tional Animal Care and Use Committee of the University of Arizona, and
conformed with NIH guidelines for the care and use of laboratory animals.Biophysical Journal 108(6) 1484–1494RESULTS
Muscle mechanics
Ca2þ-sensitive tension development
AMPK targets cTnI by phosphorylation at ser150, increasing
the sensitivity of the myofilaments to Ca2þ (14–16,27). In
addition, Ca2þ sensitivity has been used to index the impact
of exogenously administered kinases such as PKA (28–30).
We asked whether the amount of LKB1 complex relative
to the activated AMPK complex would differentially impact
myofilament function. Therefore, we determined the Ca2þ-
sensitive tension development of demembranated cardiac
fibers incubated with increasing amounts of LKB1 complex
relative to activated AMPK complex. Fig. 1 displays
the Ca2þ-sensitive tension development (SL ¼ 2.2 mM)
of demembranated fibers from four treatment groups: 1)
untreated, 2) recombinant AMPK complex (rAMPK) acti-
vated with a relatively low amount of LKB1 complex to
AMPK (rAMPK/LKB1lo), 3) rAMPK activated with a rela-
tively high amount of LKB1 complex to AMPK (rAMPK/
LKB1hi), and 4) LKB1 complex alone (LKB1). Similar to
what was observed in previous work (15), when demembra-
nated fibers were treated with rAMPK/LKB1lo, the Ca2þ-
tension relationship was shifted left, indicative of an
increase in Ca2þ-sensitive tension development compared
with untreated fibers (Fig. 1 A). In contrast, Ca2þ sensitivity
was decreased in fibers treated with rAMPK/LKB1hi when
compared with untreated fibers (Fig. 1 A). Unexpectedly,
treatment with the LKB1 complex in the absence of acti-
vated rAMPK desensitized the fibers to Ca2þ compared
with the untreated group and both the rAMPK/LKB1lo
and rAMPK/LKB1hi treatment groups (Fig. 1 B).
To test the response of the myofilaments to changes in
length (LDA), the Ca2þ sensitivity of tension at a shorter
LKB1 Complex Uniquely Impacts Sarcomere 1487SL (SL ¼ 2.0 mM) was determined under each treatment
condition. The impact of an SL change (DEC50 or
DpCa50) on the Ca
2þ-tension relationship was not signifi-
cantly different among all treatment groups (Table 1). How-
ever, treatment of fibers with the LKB1 complex alone
significantly dampened the maximum tension relative to
all other groups at both SLs. Cooperativity, as indexed by
the Hill coefficient (Table 1), did not differ among the
groups studied.Rate of tension redevelopment: ktr
Considering the central role of AMPK as a regulator of
cellular energy homeostasis, we wished to determine the
impact of the different treatment protocols on measures of
cross-bridge cycling. The rate constant for tension redevel-
opment (ktr) measures the sum of the apparent rates with
which the actin-myosin cross-bridges enter and leave ten-
sion-generating states (31). Fig. S1 B shows representative
tension recordings after a ktr protocol at activating [Ca
2þ]
for each of the experimental conditions. There were no
differences in maximal, or Ca2þ saturating, ktr (Table 1) be-
tween the treatment groups.
As ktr is dependent on both levels of activating Ca
2þ and
strongly bound cross-bridges, we determined ktr over a
range of submaximal activating Ca2þ, plotted against rela-
tive tension (Fig. 2) and fit by linear regression (Table 1).
In addition to an increase in Ca2þ sensitivity, rAMPK/
LKB1lo-treated fibers displayed a significantly steeper ten-
sion-ktr linear relationship compared with untreated fibers.
However, the relationship between tension and ktr over the
range of activating Ca2þ is curvilinear in striated muscle
and is best fit with nonlinear regression (31). Even with aTABLE 1 Ca2D sensitivity of tension
Untreated (n ¼ 13) rAMPK:LKB
EC50 (mM) 2.585 0.11 1.565
pCa50 5.595 0.02 5.815
Hill coefficient 5.045 0.44 5.315
DEC50 0.585 0.10 0.595
DpCa50 0.085 0.02 0.135
Maximum tension (mN/mm2) 33.985 2.32 (n ¼ 36) 35.335 4.0
Tension Redevelopment
Untreated (n ¼ 10) rAMPK:LK
ktr max (s
1) 5.285 0.27 6.14
Linear fit (s1/P/P0) 4.195 0.48 6.16
Monoexponential fit (s1/P/P0) 2.265 0.59 10.02
Each column contains mean values5 SE. Cardiac trabeculae were untreated or
LKB1lo), high amounts of activating LKB1 complex to AMPK (rAMPK:LKB1h
sion for each group is indicated by EC50 (mM) and pCa50. There is an increase
decrease in Ca2þ sensitivity in the rAMPK/LKB1hi group (p< 0.001), and an ev
(p< 0.001). A one-way ANOVA indicated that all EC50 values were different fro
LDA (DEC50, DpCa50) between SLs of 2.2 mm and 2.0 mm. Maximum tension g
generation (p < 0.05). In an additional set of skinned fibers, the relationship betw
fit to the data. Slopes for each fit are reported above. There is an increase in the slo
or monoexponential fit (p < 0.05) compared with untreated fibers. *, statisticalcurvilinear fit to the tension-ktr relationship, rAMPK/
LKB1lo-treated fibers displayed a significantly steeper slope
compared with untreated fibers. Interestingly, the presence
of activated rAMPK regardless of the amount of LKB1
complex resulted in a decreased ktr at submaximal tension
(Fig. 2). However, LKB1-complex-treated fibers in the
absence of activated rAMPK displayed a similar ktr at all
activation levels.Phosphorylation of sarcomeric proteins
Global phosphorylation status
Sarcomeric proteins are targets for multiple kinases and
remain a central integration site for regulatory signaling
cascades. As a result of these signaling cascades, PTM of
myofilament proteins has known effects on Ca2þ sensitivity
(28), the cross-bridge cycling rate (32) and Ca2þ binding
characteristics (33). Considering the differential impact
on Ca2þ sensitivity and tension redevelopment (ktr), we
hypothesized that rAMPK/LKB1lo, rAMPK/LKB1hi, and
LKB1 treatment would similarly have a differential effect
on sarcomeric protein phosphorylation. Using SDS-PAGE
followed by Pro-Q Diamond phosphoprotein staining, we
were able to identify and quantify global phosphorylation
levels of key myofilament proteins, including MBPC,
desmin, cardiac troponin T (cTnT), cardiac tropomyosin
(cTm), cTnI, and myosin light chain 1 (MLC-1). We found
no measurable alteration in overall phosphorylation status
in any of the activated rAMPK-treated groups. However,
there was a detectable increase in MBPC phosphorylation
in fibers treated with only the exogenous LKB1 complex
(Fig. 3).1lo (n ¼ 8) rAMPK:LKB1hi (n ¼ 6) LKB1 (n ¼ 6)
. 06* 3.715 .17* 4.165 .12*
0.02* 5.435 0.02* 5.385 0.01*
0.61 3.985 0.58 6.975 2.29
0.06 0.605 0.17 0.435 0.08
0.04 0.075 0.03 0.035 0.01
7 (n ¼ 14) 30.025 2.62 (n ¼ 18) 21.505 1.71* (n ¼ 27)
B1lo (n ¼ 12) rAMPK:LKB1hi (n ¼ 10) LKB1 (n ¼ 11)
5 0.41 4.915 0.25 5.355 0.54
5 0.71* 5.085 0.46 3.595 0.37
5 2.37* 4.715 0.73 3.965 1.11
treated with low amounts of activating LKB1 complex to AMPK (rAMPK/
i), or exogenous LKB1 complex alone (LKB1). The Ca2þ sensitivity of ten-
in Ca2þ sensitivity in the rAMPK/LKB1lo group (p < 0.001). There is a
en further decrease in Ca2þ sensitivity is seen with the LKB1 complex alone
m one another. There was no difference in cooperativity (Hill coefficient) or
eneration was also determined; LKB1 complex treatment decreased tension
een ktr and tension was determined with both a linear and monoexponential
pe between ktr and tension in the rAMPK/LKB1
lo group regardless of linear
ly significant difference.
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FIGURE 2 Rate constant for tension redevelopment. ktr is plotted as a function of normalized tension for fibers treated with low LKB1 activation of AMPK
(rAMPK/LKB1lo), high LKB1 activation of AMPK (rAMPK/LKB1hi), and LKB1 complex alone (LKB1) plotted relative to untreated fibers. (A–C) Data
were binned and fitted to a curvilinear fit. There is a significant increase in the slope of rAMPK/LKB1lo-treated fibers compared with untreated fibers
(p < 0.05). rAMPK/LKB1hi-treated fibers tend to have an increased slope compared with untreated fibers. There is no difference between curvilinear slopes
between LKB1-complex-treated fibers and untreated fibers. (D–F) Raw data were fitted with a linear regression, and multiple linear regression analysis was
used to measure differences between slopes. There is a significant increase in the slope in fibers treated with rAMPK/LKB1lo (p< 0.05). There is a tendency
for an increased slope with rAMPK/LKB1hi-treated fibers, with a significantly different intercept (p < 0.05) compared with untreated fibers. There is no
difference in linear slopes between LKB1-complex-treated and untreated fibers.
1488 Behunin et al.Western blot site-specific phosphorylation status
cTnI. Although no differences in total phosphorylation
were determined by Pro-Q Diamond phosphoprotein stain-
ing (Fig. 3), it remains possible that each treatment strategyFIGURE 3 ProQ Diamond phosphoprotein stain after treatment with and
without various activated AMPKs and the LKB1 complex. (A) Representa-
tive lanes (n ¼ 4 per treatment group) from the same gel stained first for
phosphorylation (ProQ Diamond) and then for total protein content (Coom-
massie Brilliant Blue). Protein identification as shown on the left was based
on the molecular weights of known myofibrillar proteins. (B) The relative
optical density of the phosphoprotein signal was normalized for loading
by dividing the ProQ Diamond signal by the corresponding Coomassie
Brilliant Blue signal per protein. There is a significant increase in phosphor-
ylation of MBPC in skinned trabeculae treated with only exogenous
LKB1 complex compared with all other groups (p< 0.05; n¼ 4 per group).
In all other proteins, there is no significant change in global phosphoryla-
tion status.
Biophysical Journal 108(6) 1484–1494resulted in a unique pattern of site-specific phosphorylation.
Because AMPK is known to specifically target ser150 of
cTnI (16), we first determined whether different amounts
of the LKB1 complex could impact the ability of activating
rAMPK to phosphorylate ser150 of cTnI by Western blot
analysis using a phospho-ser150cTnI-specific antibody. As
shown in Fig. 4, ser150-cTnI was robustly phosphorylated
(phospho-ser150cTnI) in the presence of activated rAMPK
independently of the LKB1 complex concentration. No
difference in phospho-ser150cTnI was detected between
untreated and LKB1-complex-treated groups.
AMPK, among other kinases, is capable of targeting
ser23/24 of cTnI (16). In this study, we confirmed that acti-
vated rAMPK targeted and phosphorylated ser23/24-cTnI to
a level that reached significance compared with controls
only in the presence of high LKB1 (rAMPK/LKB1hi). Phos-
pho-ser23/24cTnI levels in fibers treated with rAMPK/
LKB1lo or LKB1 complex alone were unchanged from
controls (Fig. 4). We also examined the PKC site, ser43cTnI,
and found no changes in phospho-ser43cTnI content in any
experimental group (Fig. 4).
MBPC. Pro-Q Diamond phosphoprotein staining suggests
that the unique AMPK/LKB1 treatments impact the post-
translational pattern of MBPC phosphorylation. MBPC is
targeted by many kinases at multiple phosphorylation sites
FIGURE 4 Western blot analysis of phos-
phorylated cTnI. The Western blot depicts
phospho-cTnI in myofibrils treated with various
stoichiometric LKB1 activations of AMPK and
the LKB1 complex, with the corresponding
normalized optical density plotted on the right.
(A) Phospho-ser23/24 cTnI was measured in treated
and untreated myofibrils. Fibers treated with a high
level of LKB1 activation of AMPK (rAMPK/
LKB1hi) had a significant increase in phosphory-
lated ser23/24 content relative to untreated myofi-
brils (p < 0.05; n ¼ 4 for all groups). (B)
Phospho-ser150 cTnI was measured in treated and
untreated myofibrils. There was a significant in-
crease in phosphorylated ser150 in rAMPK/
LKB1hi- and rAMPK/LKB1lo-treated fibers (p <
0.05; n ¼ 3–4 per group). (C) Phospho-ser43cTnI
was measured in treated and untreated myofibrils.
There was no change in phospho-ser43cTnI in any
treatment group (p > 0.05).
LKB1 Complex Uniquely Impacts Sarcomere 1489(34), but to our knowledge, this study is the first to implicate
MPBC as a potential target of the LKB1/AMPK signal-
ing axis. Accordingly, we determined phosphorylation of
MBPC at one of these sites (phospho-ser282MBPC) as an
initial examination of this novel (to our knowledge)
AMPK targeting. We found that fibers treated with
rAMPK/LKB1lo showed a level of phospho-ser282MBPC
that was significantly elevated compared with control fibers
only (Fig. 5). Interestingly, this is different from the global
elevation in MBPC phosphorylation in the LKB1-treated
group as determined by Pro-Q Diamond phosphoprotein
(Fig. 3). This is most likely due to potential differences in
alternative MBPC phosphorylation sites as detailed in the
Discussion.
Phosphate-affinity SDS-PAGE
cTnI harbors multiple phosphorylation sites, including the
PKA sites ser23/ser24, the protein kinase C sites ser43/45FIGURE 5 Western blot analysis of phosphorylated MBPC. The Western
blot depicts phospho-ser282MPBC in myofibrils treated with activated
AMPK and the LKB1 complex. The phosphorylated signal was normalized
to total MBPC, and the corresponding normalized optical density is plotted
on the right. Fibers treated with a low level of LKB1 activation of AMPK
(rAMPK/LKB1lo) had a significant increase in phosphorylated ser282 con-
tent relative to untreated myofibrils (*p < 0.05; n ¼ 4 for all groups).and thr144, and the p-21 activated kinase/AMPK site ser150
(35). It has been suggested that the specific distribution of
cTnI phosphorylation along its multiple phosphorylation
sites can uniquely impact myofilament behavior (36,37).
Therefore, we were interested in the overall distribution of
cTnI phosphospecies in response to each treatment condi-
tion. We used the strategy of SDS-PAGE-Phos-tag coupled
with phospho-specific antibodies to separate and measure
the relative distribution of cTnI phosphospecies.
Using an antibody that recognizes total cTnI regardless
of phosphorylation status, we found three distinct cTnI
groups (Fig. 6) that have been designated by convention
as the unphosphorylated (0P), monophosphorylated (1P),
and bisphosphorylated (2P) species of phospho-cTnI. As ex-
pected, the summed densitometry of all three cTnI bands
was not different among the groups studied. There was no
change in cTnI phosphospecies distribution in fibers treated
with LKB1 complex alone. Interestingly, when the same
molar amount of LKB1 complex was added to the fibers
in the presence of rAMPK, there was a shift in the distribu-
tion of cTnI (Fig. 6, rAMPK/LKB1hi). Fibers treated with
rAMPK/LKB1hi had a shifted cTnI phosphospecies distri-
bution away from the 0P unphosphorylated state toward
the 2P bisphosphorylated state. The distribution away
from the 0P state was also mirrored in the fibers treated
with rAMPK/LKB1lo (Fig. 6, rAMPK/LKB1lo).
Phosphate-affinity SDS-PAGE was then performed again
on cTnI using site-specific antibodies to phosphorylated
ser23/24 and ser150 to determine the relative content of
each cTnI phosphospecies. Cross-reactivity of the phos-
pho-ser23/24 cTnI antibody with hcTnI at high concentra-
tions (Fig. S2) identifies the 0P band and indicates the
presence of phospho-ser23/24 cTnI in the 1P and 2P state.Biophysical Journal 108(6) 1484–1494
FIGURE 6 Phosphate-affinity SDS-PAGE (Phos-tag) of the total cTnI
phosphospecies distribution. cTnI was separated into unphosphorylated
[0P], monophosphorylated [1P], and bisphosphorylated [2P] phosphospe-
cies by SDS-PAGE-Phos-tag followed by Western blot analysis with a total
cTnI antibody. Top panel: representative SDS-PAGE-Phos-tag followed
by Western blot, illustrating three bands corresponding to 0P, 1P, and 2P.
Human recombinant cTnI (hcTnI) and PKA-treated (þPKA) cardiomyo-
cytes were used to confirm each phosphospecies. Bottom panel: stacked
bar graph indicating the relative amounts of each phosphospecies per exper-
imental group. There is a significant shift in fibers treated with both high
and low LKB1 activation of AMPK (rAMPK/LKB1hi and rAMPK:LKB1lo)
away from the 0P state (p < 0.05). There is no change in total cTnI phos-
phospecies distribution in the LKB1-complex-treated group.
FIGURE 7 Phosphate-affinity SDS-PAGE (Phos-tag) of the phospho-
ser23/24 cTnI phosphospecies distribution. cTnI was separated into unphos-
phorylated [0P], monophosphorylated [1P], and bisphosphorylated [2P]
phosphospecies by SDS-PAGE-Phos-tag followed by Western blot analysis
with a phospho-ser23/24 cTnI antibody. Top panel: representative SDS-
PAGE-Phos-tag followed by Western blot, illustrating two distinct bands
corresponding to 1P and 2P. Human recombinant cTnI (hcTnI) and PKA-
treated (þPKA) cardiomyocytes were used to confirm each phosphospe-
cies. Bottom panel: stacked bar graph indicating the relative amounts of
each phosphospecies per experimental group. There is a significant increase
in 2P phospho-ser23/24cTnI in rAMPK/LKB1hi- and rAMPK/LKB1lo-
treated fibers (p< 0.05). In addition, rAMPK/LKB1hi-treated fibers contain
more 2P phospho-ser23/24cTnI than rAMPK/LKB1lo-treated fibers. There
was no change in the group treated only with LKB1 complex.
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band for both rAMPK/LKB1hi and rAMPK/LKB1lo, with
rAMPK/LKB1hi having the most overall phospho-ser23/24
in the 2P state (Fig. 7).
Similarly to our previous study, we were able to detect
phosphorylation at phospho-ser150 cTnI in the 0P, 1P, and
2P bands, indicating the existence of phospho-ser150 cTnI
in at least three states of cTnI phosphorylation (26). How-
ever, there was no overall change in the distribution of phos-
pho-ser150 cTnI phosphospecies among groups (Fig. 8).
Therefore, the different ratios of LKB1 activation of
AMPK will shift cTnI phosphospecies distribution toward
the 2P state, but the fibers treated with rAMPK/LKB1hi
will have a greater phospho-ser23/24 content in the bisphos-
phorylated state than fibers treated with rAMPK/LKB1lo. It
should also be noted that fibers treated with LKB1 complex
alone showed no change in phospho-ser23/24 and phospho-
ser150 cTnI phosphospecies distribution (Figs. 7 and 8).DISCUSSION
Energetic remodeling is a hallmark of cardiac disease pro-
gression regardless of disease etiology. A disturbance in
the CK/AK phosphotransfer system is observed early onBiophysical Journal 108(6) 1484–1494and, importantly, is a stronger predictor of heart failure mor-
tality than functional status (9). It is now appreciated that
the driver for metabolic remodeling is the ATP requirement
from myocellular ATP consumers such as myosin (2,38,39).
Therefore, elucidating the underlying mechanisms of ener-
getic remodeling requires a clear understanding of the costs
of contraction. Consequently, we chose to examine the
LKB1/AMPK signaling axis because it is uniquely posi-
tioned to respond to the changing energetic environment
while modifying contractile function by directly targeting
myofilament proteins. However, AMPK activity is subject
to localized regulation by AMP pools. In addition, LKB1
target activation depends on its subcellular localization
and transcriptional expression (4,18–20,40). Therefore, we
hypothesized that the amount of the LKB1 complex relative
to activated AMPK will uniquely impact myofilament func-
tion. We chose to use maximally activated AMPK and then
vary the amount of LKB1, assuming that this would most
appropriately represent in vivo conditions. The major find-
ings from this study are that 1) the Ca2þ sensitivity of ten-
sion and cross-bridge cycling are dependent on the LKB1/
AMPK ratio, 2) the LKB1 complex impacts contractile
function independently of exogenous AMPK, 3) the pattern
FIGURE 8 Phosphate-affinity SDS-PAGE (Phos-tag) of the phospho-
ser150 cTnI phosphospecies distribution. cTnI was separated into unphos-
phorylated [0P], monophosphorylated [1P], and bisphosphorylated [2P]
phosphospecies by SDS-PAGE-Phos-tag followed by Western blot analysis
with a phospho-ser150 cTnI antibody. Top: representative SDS-PAGE-Phos-
tag followed by Western blot illustrating two or three distinct bands corre-
sponding to 0P, 1P, and 2P. hcTnI was used as the unphosphorylated cTnI
standard. Bottom: stacked bar graph indicating the relative amounts of
each phosphospecies per experimental group. There was no change in the
distribution of phospho-ser150 cTnI phosphospecies among groups.
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alters cTnI phosphorylation, and 4) the LKB1 complex
alone targets the myofilament, potentially through MBPC.
To best preserve the native state of myofilament proteins,
we used intact demembranated cardiac fibers (trabeculae or
cut papillaries) for incubation with each of the treatment
protocols. Similar to what was observed in previous studies
(15), we found that a lower LKB1/AMPK (rAMPK/LKB1lo)
sensitizes the myofilaments to Ca2þ, shifting the Ca2þ-
tension curve to the left. However, a higher molar ratio of
LKB1 complex to AMPK (rAMPK/LKB1hi) desensitizes
the myofilaments to Ca2þ, shifting the Ca2þ-tension curve
to the right. Unexpectedly, when only exogenous LKB1
complex is incubated with cardiac trabeculae, the myofila-
ments are even further desensitized to Ca2þ. In addition,
fibers treated with rAMPK/LKB1lo demonstrate a reduced
ktr compared with untreated fibers at submaximal Ca
2þ con-
centrations (31). Because Ca2þ-saturated (maximal) ktr is
not different, the net result of a reduced submaximal ktr is
a steeper tension-ktr relationship compared with all other
groups.
The significance of this finding can be illustrated using
a simplified two-state, cross-bridge model in which the
rate of tension redevelopment, ktr, is proportional to both
the attachment and detachment rates. Using this model,
we predict that the dominant mechanism responsible for
the lower, submaximal ktr is a decrease in the cross-bridgedetachment rate. The implication from these data is a poten-
tial economizing of tension with AMPK treatment. In sup-
port of this contention, Oliveira et al. (14) demonstrated
that treatment of ventricular myocytes with the AMPK
activator 5-aminoimidazole-4-carboxamide ribonucleotide
increases myocyte contractility without changing the ampli-
tude of the Ca2þ transient. Although an increased sensitivity
to Ca2þ may contribute to this observation, it is likely that a
delay in cross-bridge detachment, evidenced by a decreased
ktr as measured in this study, prolongs cross-bridge attach-
ment and increases cell shortening. Similarly, a modest
prolonged time to relaxation may indicate slower rates of
cross-bridge detachment under AMPK activation. The abil-
ity of AMPK to provide an energetic benefit at the level of
the myofilament is consistent with an energy-sparing func-
tion of AMPK activation, and may represent a fundamental
mechanism by which AMPK impacts myofilament function
and protects against a reduced ATP pool.
Still, the underlying mechanism that drives changes in
myofilament function remains to be determined. PTMs of
specific serine/threonine residues play a critical role in regu-
lating parameters of myofilament function, including Ca2þ
sensitivity, cross-bridge cycling, and passive tension (36).
Consistent with an increase in Ca2þ sensitivity of tension
and with previous studies (14,16), we found that incubation
of rat cardiac trabeculae with activated AMPK regardless of
the amount of LKB1 complex resulted in an increase in
phospho-ser150cTnI relative to untreated controls.
Nixon et al. (15) previously demonstrated that the in-
crease in Ca2þ sensitivity in fibers containing cTnI pseudo-
phosphorylated at ser150 is blunted in the presence of cTnI
pseudophosphorylated at ser23/24. Therefore, we also exam-
ined the phosphorylation status of ser23/24-cTnI. Western
blot analysis indicated that there is also an overall increase
in ser23/24 phosphorylation in rAMPK/LKB1hi-treated
fibers. AMPK is capable of targeting ser23/24-cTnI, but the
kinetic parameters of target-specific phosphorylation sug-
gest that ser150 is the preferential site for activated AMPK
(16). Our data indicate that increasing the amount of the
LKB1 complex shifts the AMPK preferred site from ser150
to ser23/24. The implication is that the increase in phospho-
ser23/24 blunts AMPK-dependent Ca2þ sensitization.
However, our data also implicate an increase in LKB1 as
a potential desensitization agent.
Apart from the changes in Ca2þ sensitivity, the reduction
of submaximal ktr cannot be wholly attributable to PTM of
cTnI. An increase in cTnI-ser23/24 phosphorylation acceler-
ates ktr in the murine myocardium (41). Our data suggest
that the presence of AMPK and LKB1 blunts the impact
of cTnI-ser23/24 phosphorylation on ktr. This may be due to
PTM of alternative myofilament proteins or to a unique
localization/association of the LKB1/AMPK with the myo-
filaments, altering the cross-bridge kinetics. Future studies
are required to determine the molecular mechanisms of
these observations. These studies support the notion thatBiophysical Journal 108(6) 1484–1494
1492 Behunin et al.controlling the relative activation of AMPK through the
LKB1 complex is a potential mechanism for fine-tuning
contractile dynamics through phosphorylation.
To better illustrate the distribution of phosphorylation
sites on cTnI, we implemented SDS-PAGE-Phos-tag fol-
lowed by site-specific Western blotting with cTnI-specific
antibodies. We detected three distinct bands of cTnI desig-
nated, by convention, as 0P, 1P, and 2P, with 2P containing
the largest phospho-cTnI population (26,42). In general, the
pattern of increased phosphorylation with activated AMPK
treatment regardless of the amount of LKB1 parallels the
Western blot data obtained using SDS-PAGE without
Phos-tag: there is a shift in phosphospecies distribution
away from the 0P toward the 2P state. Although there is a
discrepancy when the total ser150-cTnI phosphospecies is
examined by SDS-PAGE-Phos-tag, the ser150-cTnI phos-
phospecies tends to exist predominantly in the 2P band.
The latter observation is most likely due to the increase in
ser23/24-cTnI phosphorylation, which is clearly elevated
whether it is determined by traditional Western blotting or
SDS-PAGE-Phos-tag.
Because multiple kinase pathways converge on cTnI,
resulting in at least 10 possible phosphorylation sites (36),
we can conclude that the categorization of each band as
un-, mono-, or bisphosphorylated may underrepresent the
existence and number of alternative cTnI phosphospecies.
The SDS-PAGE-Phos-tag technique identifies the most
abundant phosphospecies within the densitometric range
only. In this study, therefore, we cannot rule out the exis-
tence of other phosphospecies as indicated in previous
work (25). This contention is supported by the presence of
phospho-ser150cTnI in the presumably unphosphorylated
0P band. We previously demonstrated that a custom-made
phospho-ser150cTnI antibody detects cTnI only when
phosphorylated at ser150 of cTnI (26). In this study, using
a different, commercially available phospho-ser150cTnI
antibody (see Materials and Methods), we again detected
phospho-ser150cTnI in the 0P band (Fig. 7). Nevertheless,
SDS-PAGE-Phos-tag remains an extremely useful tool for
highlighting unique and distinct patterns of cTnI phosphor-
ylation (and other phospho-species such as MBPC (43)) in
response to signaling pathway activation.
Interestingly, the LKB1 complex’s interaction with the
myofilament seems to occur by two mechanisms: through
activation of the AMPK complex (as described above) or
through an AMPK-independent mechanism. In our study,
the LKB1 complex alone could decrease the Ca2þ sensi-
tivity of tension development and maximum tension gener-
ation independently of exogenous AMPK. In contrast to
AMPK-treated groups, LKB1 complex treated fibers had
no changes to the phosphorylation status of cTnI, both glob-
ally or a site-specific distribution of cTnI phosphospecies.
We identify PTM of MBPC as a potential novel (to our
knowledge) mechanism for LKB1 to act independently of
AMPK. However, when we probed for changes in PTM atBiophysical Journal 108(6) 1484–1494a known phosphorylation site on MBPC, we found a
discrepancy between global phosphorylation as measured
by Pro-Q Diamond phosphoprotein staining and a single
phosphorylation site, specifically phospho-ser282MBPC.
This is not surprising considering that MBPC harbors
multiple phosphorylation sites, all of which contribute to
the summed, global phosphorylation level. Again, we posit
that the pattern of site-specific phosphorylation may better
represent the summed effect of these many kinase pathways.
Future studies to identify the impact of the LKB1/AMPK
pathway on site-specific changes in MBPC phosphorylation
are warranted.
It is also likely that LKB1-dependent changes in myo-
filament function may operate through direct association
of the LKB1 complex with myofilament proteins. Indeed,
certain isoforms of AMPK have been shown to target sarco-
meres at the Z disc (44), which could affect localized molar
ratios of LKB1 and activating AMPK complex. However,
further investigation of LKB1’s association with the myofil-
ament is required.CONCLUSION
The LKB1/AMPK signaling axis is a promising target for
heart failure, and thus a clear understanding of this complex
regulatory system is required. We show that this signaling
pathway has the capability to impact myofilament function
through two independent means. One pathway is through an
LKB1-dependent activation of AMPK. In this system,
changing stoichiometric activation of AMPK will change
the Ca2þ sensitivity of tension, cross-bridge cycling, and
the specific content and distribution of cTnI phosphospe-
cies. Another pathway can operate seemingly independently
of AMPK: the LKB1 complex alone can target the myofila-
ment (potentially through MBPC), altering tension gene-
ration and the Ca2þ sensitivity of tension. Future studies
will be directed toward elucidating the mechanism of action
for the LKB1 complex and understanding the complex
relationship among adenine nucleotides, LKB1, AMPK,
and PTM of myofilament proteins.SUPPORTING MATERIAL
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